Therapeutic targeting of GDF11 in muscle atrophy: Insights and strategies
- PMID: 39236952
- DOI: 10.1016/j.ijbiomac.2024.135321
Therapeutic targeting of GDF11 in muscle atrophy: Insights and strategies
Abstract
The exploration of novel therapeutic avenues for skeletal muscle atrophy is imperative due to its significant health impact. Recent studies have spotlighted growth differentiation factor 11 (GDF11), a TGFβ superfamily member, for its rejuvenating role in reversing age-related tissue dysfunction. This review synthesizes current findings on GDF11, elucidating its distinct biological functions and the ongoing debates regarding its efficacy in muscle homeostasis. By addressing discrepancies in current research outcomes and its ambiguous role due to its homological identity to myostatin, a negative regulator of muscle mass, this review aims to clarify the role of GDF11 in muscle homeostasis and its potential as a therapeutic target for muscle atrophy. Through a thorough examination of GDF11's mechanisms and effects, this review provides insights that could pave the way for innovative treatments for muscle atrophy, emphasizing the need and strategies to boost endogenous GDF11 levels for therapeutic potential.
Keywords: GDF11; Growth differentiation factor 11; Muscle atrophy; TGFβ superfamily; Therapeutic strategy.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
A GDF11/myostatin inhibitor, GDF11 propeptide-Fc, increases skeletal muscle mass and improves muscle strength in dystrophic mdx mice.Skelet Muscle. 2019 May 27;9(1):16. doi: 10.1186/s13395-019-0197-y. Skelet Muscle. 2019. PMID: 31133057 Free PMC article.
-
Pathophysiological levels of GDF11 activate Smad2/Smad3 signaling and induce muscle atrophy in human iPSC-derived myocytes.Am J Physiol Cell Physiol. 2022 Nov 1;323(5):C1402-C1409. doi: 10.1152/ajpcell.00341.2022. Epub 2022 Sep 12. Am J Physiol Cell Physiol. 2022. PMID: 36094432
-
DA-Raf and the MEK inhibitor trametinib reverse skeletal myocyte differentiation inhibition or muscle atrophy caused by myostatin and GDF11 through the non-Smad Ras-ERK pathway.J Biochem. 2022 Jan 7;171(1):109-122. doi: 10.1093/jb/mvab116. J Biochem. 2022. PMID: 34676394
-
The role of GDF11 in aging and skeletal muscle, cardiac and bone homeostasis.Crit Rev Biochem Mol Biol. 2019 Apr;54(2):174-183. doi: 10.1080/10409238.2019.1610722. Crit Rev Biochem Mol Biol. 2019. PMID: 31144559 Review.
-
The Growth Differentiation Factor 11 (GDF11) and Myostatin (MSTN) in tissue specific aging.Mech Ageing Dev. 2017 Jun;164:108-112. doi: 10.1016/j.mad.2017.04.009. Epub 2017 May 1. Mech Ageing Dev. 2017. PMID: 28472635 Review.
Cited by
-
Annual Banned-Substance Review 17th Edition-Analytical Approaches in Human Sports Drug Testing 2023/2024.Drug Test Anal. 2025 Aug;17(8):1417-1442. doi: 10.1002/dta.3835. Epub 2024 Dec 28. Drug Test Anal. 2025. PMID: 39731401 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources